Anavex Life Sciences Corp (AVXL)

[falconer66a]

The Share Price Ascent Has Begun

If just half of 7 million of the Alzheimer’s patients in the EU are prescribed Anavex’s blarcamesine at just $15.00 per oral pill per day, that would generate sales per year of over $19 BILLION in sales in the EU alone.

Should one wish, with an 8th-grader’s arithmetic skills, most easily on a spreadsheet, the ranges of Anavex’s annual revenues in a few years, can be determined.

Here are numbers to plug into the calculations.

First, presume (conservatively) that there will be 100,000,000 AVXL shares in circulation. Presently, there are about 82,090,000.

Then, go to the Internet and find the numbers of Alzheimer’s patients in various markets, in the US, in Europe, in Australia, et al.

Next, determine potential per-day Anavex drug costs for the treatment of Alzheimer’s. On the low end, a mere $1.00 per day. In the middle, $10 or $15. Then, at least for a while, at the start, $25.

Use the arithmetic Mrs. Dorglemyer, your 8th grade math teacher taught you, to then determine (by multiplication) Anavex’s annual revenues for each of the various economic regions, at each of the potential daily drug costs.

With those calculations — as it appears to be the case right now — the taking of a new or expanded holding of AVXLs becomes very favorable.

Just a while ago, the AVXL share price cracked the $10 barrier, and is heading up. Combining the spreadsheet numbers with today’s, and future Anavex announcements, there will be massive AVXL share price increases. For those who can hold and see out for a year or more, generational wealth will be in sight — eventually realized.